Trial Profile
A Phase II Open-label Study of the Efficacy and Safety of Recombinant Human Arginase 1 (PEG-BCT-100) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Bio-Cancer Treatment International
- 27 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 26 Sep 2016 New trial record